Hantech Bio-Technology Valuation
Is 1294 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Book gegen Gleichaltrige
Price-To-Book gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 1294 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von 1294 für die Bewertungsanalyse.
Deutlich unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von 1294 für die Bewertungsanalyse.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1294?
Other financial metrics that can be useful for relative valuation.
What is 1294's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | NT$5.30b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | n/a |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 1294's PB Ratio compare to its peers?
Company | Forward PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 2.1x | ||
1783 Maxigen Biotech | 3x | n/a | NT$4.1b |
1731 Maywufa | 1.7x | n/a | NT$3.6b |
8480 Taisun Int'l (Holding) | 1.7x | n/a | NT$3.3b |
6666 Luo Lih-Fen Holding | 2x | n/a | NT$3.3b |
1294 Hantech Bio-Technology | n/a | n/a | NT$5.3b |
Price-To-Book gegen Gleichaltrige: Price-To-Book Unzureichende Daten für die Berechnung des Verhältnisses von 1294 zu anderen Unternehmen für die Bewertungsanalyse.
Price to Earnings Ratio vs Industry
How does 1294's PE Ratio compare vs other companies in the TW Personal Products Industry?
Price-To-Book gegen Industrie: Unzureichende Daten zur Berechnung des Verhältnisses 1294's Price-To-Book im Vergleich zur Branche für die Bewertungsanalyse.
Price to Book Ratio vs Fair Ratio
What is 1294's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | n/a |
Fair PB Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Book Fair Ratio von 1294 für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.